Heat shock proteins HSP27, HSP60, HSP70, and HSP90: Expression in bladder carcinoma

Cancer

Volumn 98, Issue 5, 2003, Pages 970-977

  Lebret, Thierry ^a,b   Watson, R William G ^b   Molinié, Vincent ^a   O'Neill, Amanda ^b   Gabriel, Christophe ^a   Fitzpatrick, John M ^b   Botto, Henry ^a  

^a FOCH HOSPITAL   (France)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Apoptosis; Bladder carcinoma; Heat shock protein; Neoplasm

Indexed keywords

HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90;

APOPTOSIS; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; APOPTOSIS; CARCINOMA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROGNOSIS; URINARY BLADDER NEOPLASMS;

EID: 0041386300     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11594     Document Type: Article

References (47)

1. Johansson SL, Cohen SM. Epidemiology and etiology of bladder cancer. Semin Surg Oncol. 1997;13:291-298.
2. Fitzpatrick JM, West AB, Butler MR, Lane V, O'Flynn JD. Superficial bladder tumors (Stage pTa, Grades 1 and 2): the importance of recurrence pattern following initial resection. J Urol. 1986;135:920-922.
3. Herr HW. Natural history of superficial bladder tumors: 10- to 20-year follow-up of treated patients. World J Urol. 1997;15:84-88.
4. Stein JP, Grossfeld GD, Ginsberg DA, et al. Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol. 1998;160:645-659.
5. Kausch I, Böhle A. Molecular aspects of bladder cancer III. Prognostic markers of bladder cancer. Eur Urol. 2002;41:15-29.
6. Lindquist S, Craig EA. The heat shock proteins. Annu Rev Genet. 1988;22:631-677.
7. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature. 1991;351:453-456.
8. Ciocca DR, Clark GM, Tandon AK, et al. Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implication. J Natl Cancer Inst. 1993;85:570-574.
9. Kaufmann SHE. Heat shock proteins and the immune response. Immunol Today. 1990;11:129-136.
10. Fuller KJ, Issels RD, Slosman DO, Guillet JG, Soussi T, Polla BS. Cancer and the heat shock response. Eur J Cancer. 1994;30A:1884-1891.
11. Lebret T, Watson RW, Fitzpatrick JM. Heat shock proteins: their role in urological tumors. J Urol. 2003;169:338-346.
12. Bostwick DG, Mikuz G. Urothelial papillary (exophytic) neoplasm. Virchows Arch. 2002;441:109-161.
13. Sobin LH, Wittekind C, editors. TNM classification of malignant tumors (5th edition). New York: John Wiley & Sons, 1997.
14. Vanmuylder N, Evrard L, Daelemans P, Van Reck J, Dourov N. Immunohistochemical expression of heat shock proteins HSP27, HSP70 HSP90 and HSP110 in salivary gland tumors: a study of 50 cases. Ann Pathol. 2000;20:190-195.
15. Brandau S, Bohle A. Bladder cancer. Molecular and genetic basis of carcinogenesis. Eur Urol. 2001;39:491-497.
16. Schneider J, Jimenez E, Marenbach K, Romero H, Marx D, Meden H. Immunohistochemical detection of HSP60-expression in human ovarian cancer. Correlation with survival in a series of 247 patients. Anticancer Res. 1999;19:2141-2146.
17. Cardillo MR, Sale P, Di Silverio F. Heat shock protein-90, IL-6 and IL-10 in bladder cancer. Anticancer Res. 2000;20:4579-4584.
18. Fuller KJ, Issels RD, Slosman DO, Guillet JG, Soussi T, Polla BS. Cancer and the heat shock response. Eur J Cancer. 1994;30A:1884-1891.
19. Ciocca DR, Oesterreich S, Chamness GC, McGuire WL, Fuqua SA. Biological and clinical implications of heat shock protein 27,000 (Hsp27): a review. J Natl Cancer Inst. 1993;85:1558-1570.
20. Conroy SE, Latchman DS. Do heat shock proteins have a role in breast cancer? Br J Cancer. 1996;74:717-721.
21. Jolly C, Morimoto RI. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst. 2000;92:1564-1572.
22. Gibbons NB, Watson RWG, Coffey RNT, Brady HP, Fitzpatrick JM. Heat-shock proteins inhibit induction of prostate cancer cell apoptosis. Prostate. 2000;45:58-65.
23. Welch WJ. Mammalian stress response: cell physiology, structure/function of stress proteins and application for medicine and disease. Physiol Rev. 1992;72:1063-1081.
24. Trieb K, Lang S, Kotz R. Heat-shock protein 72 in human osteosarcoma: T-lymphocyte reactivity and cytotoxicity. Pediatr Hematol Oncol. 2000;17:355-364.
25. Multhoff G, Botzler C, Issels R. The role of heat shock proteins in the stimulation of an immune response. Biol Chem. 1998;379:295-300.
26. Harada M, Kimura G, Nomoto K. Heat-shock proteins and the antitumor T cell response. Biotherapy. 1998;10:229-235.
27. Zlotta AR, Drowart A, Huygen K, et al. Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette-Guerin (BCG) in patients with superficial bladder cancer. Clin Exp Immunol. 1997;109:157-165.
28. Lebret T, Bohin D, Kassardjian Z, et al. Recurrence, progression and success in Stage Ta Grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations. J Urol. 2000;163:63-67.
29. Lebret T, Gaudez F, Hervé JM, Barré P, Lugagne PM, Botto H. Low-dose BCG instillations in the treatment of Stage T1 Grade 3 bladder tumours: recurrence, progression and success. Eur Urol. 1998;34:67-72.
30. Böhle A. BCG's mechanism of action. Increasing our understanding. Eur Urol. 2000;37(Suppl 1):1-8.
31. Zlotta AR, Drowart A, Van Vooren JP, et al. Superficial bladder tumors and increased reactivity against mycobacterial antigens before bacillus Calmette-Guerin therapy. J Urol. 1998;159:1885-1891.
32. Srivastava PK. Heat shock proteins in immune response to cancer: the Fourth Paradigm. Experientia. 1994;50:1054-1060.
33. Zlotta AR, Drowart A, Huygen K, et al. Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette-Guerin (BCG) in patients with superficial bladder cancer. Clin Exp Immunol. 1997;109:157-165.
34. Lane DP, Midgley C, Hupp T. Tumour suppressor genes and molecular chaperones. Philos Trans R Soc Lond B Biol Sci. 1993;339:369-372; discussion, 372-373.
35. Kaur J, Srivastava A, Ralhan R. Serum p53 antibodies in patients with oral lesions: correlation with p53/HSP70 complexes. Int J Cancer. 1997;74:609-613.
36. Lebret T, Becette V, Gentile A, et al. Correlation between p53 overexpression and response to bacille Calmette et Guerin therapy in a high risk select population with T1G3 bladder cancer. J Urol. 1998;159:788-791.
37. Storm FK, Mahvi DM, Glichrist KW. Hsp-27 has no diagnostic or prognostic significance in prostate or bladder cancers. Urology. 1993;42:379-382.
38. Trieb K, Kotz R. Proteins expressed in osteosarcoma and serum levels as prognostic factors. Int J Biochem Cell Biol. 2001;33:11-17.
39. King KL, Li AF, Chau GY, et al. Prognostic significance of heat shock protein-27 expression in hepatocellular carcinoma and its relation to histologic grading and survival. Cancer. 2000;88:2464-2470.
40. Kawanishi K, Shiozaki H, Doki Y, et al. Prognostic significance of heat shock proteins 27 and 70 in patients with squamous cell carcinoma of the esophagus. Cancer. 1999;85:1649-1657.
41. Cornford PA, Dodson AR, Parsons KF, et al. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res. 2000;60:7099-7105.
42. Richards EH, Hickman JA, Master JR. Heat shock protein expression in testis and bladder cancer cell lines exhibiting differential sensitivity to heat. Br J Cancer. 1995;72:620-626.
43. Wells AD, Malkovksy M. Heat shock proteins, tumor immunogenicity and antigen presentation: an integrated view. Immunol Today. 2000;21:129-132.
44. Feng H, Zeng Y, Whitesell L, Katsanis E. Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity. Blood. 2001;97:3505-3512.
45. Wang XY, Kaneko Y, Repasky E, Subjeck JR. Heat shock proteins and cancer immunotherapy. Immunol Invest. 2000;29:131-137.
46. Ménoret A, Chandawarkar R. Heat shock protein-based anticancer immunotherapy: an idea whose time has come. Semin Oncol. 1998;25:654-660.
47. Udono H, Srivastava PK. Comparison of tumor-specific immunogenicities of stress induced proteins gp96, hsp90 and hsp70. J Immunol. 1994;152:5398-5403.